FDA: Jemperli dMMR Rectal Cancer Approval Granted

• The FDA has granted accelerated approval for Jemperli (dostarlimab-gxly) to treat specific cases of locally advanced rectal cancer.
• This approval applies to adults with previously untreated stage II or III mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) rectal cancer.
• The immunotherapy may allow eligible patients to avoid conventional treatments like chemotherapy, radiation, and surgery, which carry significant side effects.
• Clinical trials, including AZUR-1, showed that a high percentage of patients treated with Jemperli did not require standard therapies.
• Jemperli works by blocking the PD-1 protein, enabling the immune system to better target dMMR/MSI-H cancer cells.

This approval represents a groundbreaking alternative for specific types of rectal cancer, potentially allowing patients to avoid surgery, radiation, and chemotherapy.

The U.S. Food and Drug Administration (FDA) has granted accelerated approval for Jemperli (dostarlimab-gxly), an immunotherapy, marking a significant advancement in the treatment of certain rectal cancer patients. This FDA Jemperli dMMR rectal cancer approval offers a new therapeutic avenue for adults diagnosed with previously untreated stage II or stage III locally advanced rectal cancer. Crucially, this innovative treatment may enable eligible individuals to bypass traditional, often debilitating, interventions such as chemotherapy, radiation, and surgery.

Standard treatments for locally advanced rectal cancer typically involve a combination of chemotherapy and radiation before surgical removal of the tumor. These conventional approaches can lead to severe and lasting side effects, including impairments to bowel, urinary, and sexual function, as well as fertility issues. Surgical procedures themselves carry inherent risks, such as poor healing, anastomotic leaks, and in some cases, the necessity of a permanent colostomy. The newly approved Jemperli aims to mitigate these life-altering consequences for a specific patient population.

The FDA's decision was primarily based on interim findings from the AZUR-1 clinical trial (NCT05723562), a phase 2 study investigating Jemperli as a standalone therapy. This trial enrolled 154 patients with previously untreated dMMR or MSI-H locally advanced rectal cancer. Participants received up to nine doses of Jemperli, administered every three weeks over a six-month period. Following a median observation period exceeding two years, the AZUR-1 clinical trial results showed that nearly three-fourths of the patients in the study did not require surgery, radiotherapy, or chemotherapy.

Further supporting the efficacy of dostarlimab-gxly approval, an earlier study conducted at Memorial Sloan Kettering Cancer Center (NCT04165772) evaluated Jemperli in 50 patients with the same specific type of rectal cancer. In this cohort, no patients exhibited detectable signs of cancer after completing Jemperli treatment. A remarkable 93% of these individuals maintained their cancer-free status for at least 12 months. Among the 27 patients who were followed for a minimum of three years, only one experienced a cancer recurrence, which occurred in the same anatomical region. While these results are promising, longer-term follow-up is still necessary to fully ascertain the durability of response and the frequency of cancer recurrence.

The specific patient group eligible for this treatment has tumors characterized as mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H). These terms describe a fundamental defect in the cancer cells' ability to correct errors that occur during DNA replication. Normally, a cellular repair system identifies and fixes these mistakes. When this system malfunctions, errors accumulate, leading to the production of abnormal proteins that the immune system can recognize. This characteristic makes dMMR/MSI-H tumors particularly susceptible to immunotherapy.

Published estimates indicate that approximately 3% of all locally advanced rectal cancers fall into the dMMR or MSI-H categories. Jemperli, an immunotherapy, functions by targeting the PD-1 protein found on immune cells. By blocking this protein, Jemperli effectively removes a protective shield that cancer cells use to evade detection and destruction by the body's immune system, thereby enhancing the immune response against the tumor. This mechanism underpins its effectiveness as a rectal cancer chemotherapy avoidance strategy for this specific patient population, offering a novel mismatch repair deficient rectal cancer treatment.

This FDA oncology accelerated approval underscores the agency's commitment to expediting access to innovative treatments for patients with unmet medical needs, particularly in oncology. Acting FDA Commissioner Kyle Diamantas, J.D., highlighted the agency's dedication to bridging the gap between scientific advancements and patient access, noting that the FDA's efforts were making timely access to innovative treatments a reality for American patients. The review process for this approval was completed nearly four months ahead of schedule, demonstrating the urgency placed on bringing this option to patients.

Dr. Angelo de Claro, director of the FDA’s Oncology Center of Excellence, emphasized that while standard rectal cancer treatment has profound life-altering effects, this approval represents a groundbreaking alternative for specific types of rectal cancer, potentially allowing patients to avoid surgery, radiation, and chemotherapy. He described this as a significant benefit for both patients and their families. The FDA's action reflects its responsiveness to emerging evidence, aiming to introduce new approaches sooner, while simultaneously requiring ongoing studies to confirm the long-term benefits of such treatments. It is important to note that Jemperli can induce immune-mediated adverse reactions, where the immune system attacks healthy organs and tissues, which can be severe or even fatal.

Lawyers advising pharmaceutical companies should note the FDA's accelerated approval pathway for Jemperli, particularly for niche patient populations (dMMR/MSI-H rectal cancer), and the implications for market access, labeling, and post-market study obligations. Healthcare compliance officers should monitor evolving treatment guidelines and insurance coverage for this new immunotherapy, which significantly alters the standard of care for eligible patients.

Source: Original reporting via FDA press release